Physician profile
David Robbins
NPI 1588848683
$79,109.20
in general payments reported to CMS, 2019-2025
30 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,718 · 2020: $25K · 2021: $8,153 · 2022: $18K · 2023: $11K · 2024: $8,249 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $4,017 · Consulting Fee: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,176.25 |
| Food and Beverage | $4,016.74 |
| Consulting Fee | $1,425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $72,678.65 | 2019-2025 | Greenlight Xps, Rezum Generator, Ams 700 |
| Janssen Biotech, INC. | $1,633.62 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $1,176.59 | 2019-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $530.96 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Abbvie INC. | $381.99 | 2019-2025 | |
| Pfizer INC. | $374.29 | 2019-2024 | |
| Tolmar Pharmaceuticals, INC. | $323.39 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $301.01 | 2023-2025 | Orgovyx, Gemtesa |
| Verity Pharmaceuticals INC. | $232.11 | 2021-2024 | Trelstar, Tlando |
| Urovant Sciences INC | $165.40 | 2021-2022 | |
| Teleflex LLC | $134.72 | 2021-2025 | Urolift, Barrigel |
| Endo USA, INC. | $126.29 | 2024-2025 | Xiaflex |
| Tolmar, INC. | $119.03 | 2023-2025 | Jatenzo, Eligard |
| Coloplast Corp | $109.95 | 2019-2021 | |
| Blue Earth Diagnostics | $103.90 | 2019-2025 | Posluma |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $88.35 | 2019-2022 | |
| Myovant Sciences INC. | $74.87 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $65.20 | 2022-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $64.26 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $62.84 | 2019-2021 | |
| Axonics, INC. | $61.40 | 2021-2024 | Axonics |
| Novartis Pharmaceuticals Corporation | $49.69 | 2023-2025 | |
| Angiodynamics, INC. | $47.72 | 2021-2025 | Nanoknife |
| Neotract INC. | $47.28 | 2019 | |
| Profound Medical Corp. | $38.91 | 2021-2022 | |
| Urogen Pharma, INC. | $37.87 | 2021-2025 | |
| Philips North America LLC | $23.45 | 2025 | Oncology Solution |
| Myriad Genetic Laboratories, INC. | $20.75 | 2022 | |
| Accord Healthcare, INC. | $19.41 | 2024 | |
| Hollister Incorporated | $15.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.